PASADENA, CA--(Marketwire - February 19, 2013) -
A research report has been issued by Market Advisors, Inc. "Fundamental Analysis for Today's Investments" on Immunotech Laboratories, Inc (PINKSHEETS: IMMB
According to the report, Immunotech Laboratories Inc. is committed to beginning clinical trials for its patented IPF Technology to treat HIV/AIDS, Cancer and Hepatitis C. Treatments for HIV/AIDS and cancer and other diseases are always welcome news and this Company appears to have some answers for these health problems which we are all being confronted with, not just here is the U.S., but globally. Immunotech Laboratories Inc. has started restructuring and has added new board members with a goal of up-listing to NASDAQ.
To see the full report please click here (http://freepdfhosting.com/7bd113ff01.pdf).
The report will also be available soon on the Immunotech Company website immunotechlab.com.
About Immunotech Laboratories, Inc.
Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV, Cancer, Hepatitis and Aids. Please visit the company website at Immunotechlab.com and see testimonials of treated patients at lifechoicemx.com
About Market Advisors, Inc.
Officers of Market Advisors, Inc. have been in business since 1983 and have provided stock market research for their clients since 1985. Company officials have often been quoted in a wide array of financial publications such as the Wall Street Journal, Investors Business Daily, Barron's, Forbes Magazine and The Dick Davis Digest to name a few.
The information and opinions in this analyst report were prepared by Market Advisors, Inc and Associates. (located in Nebraska) who does receive fees for services including preparation of this report. Officers of Market Advisors, Inc. received $2000.00 from a third party for this report. This is not an offer to buy or sell securities nor should this report be construed as investment advice. Information or statements are subject to numerous risks and uncertainties that cause such statements not to prove accurate. Market Advisors, Inc. does not disseminate, nor is it liable for the dissemination by any third party of this analyst report